These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 12711173)
21. Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. Elhissi AM; Giebultowicz J; Stec AA; Wroczynski P; Ahmed W; Alhnan MA; Phoenix D; Taylor KM Int J Pharm; 2012 Oct; 436(1-2):519-26. PubMed ID: 22796173 [TBL] [Abstract][Full Text] [Related]
22. Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology. Hernández-Trejo N; Kayser O; Steckel H; Müller RH J Drug Target; 2005; 13(8-9):499-507. PubMed ID: 16332575 [TBL] [Abstract][Full Text] [Related]
23. Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pillai R; Petrak K; Blezinger P; Deshpande D; Florack V; Freimark B; Padmabandu G; Rolland A Pharm Res; 1998 Nov; 15(11):1743-7. PubMed ID: 9833997 [TBL] [Abstract][Full Text] [Related]
24. Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. Blonski K; Schumacher U; Burkholder I; Edler L; Nikbakht H; Boeters I; Peters A; Kugler C; Horny HP; Langer M; Wilhelm-Ogunbiyi K; Witthohn K; Laack E Anticancer Res; 2005; 25(5):3303-7. PubMed ID: 16101142 [TBL] [Abstract][Full Text] [Related]
25. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Bergmann L; Aamdal S; Marreaud S; Lacombe D; Herold M; Yamaguchi T; Wilhelm-Ogunbiyi K; Lentzen H; Zwierzina H; Eur J Cancer; 2008 Aug; 44(12):1657-62. PubMed ID: 18602257 [TBL] [Abstract][Full Text] [Related]
26. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. Beck-Broichsitter M; Kleimann P; Gessler T; Seeger W; Kissel T; Schmehl T Int J Pharm; 2012 Jan; 422(1-2):398-408. PubMed ID: 22001839 [TBL] [Abstract][Full Text] [Related]
27. [Time course of drug concentrations in nebulizers and nebulized solutions]. Ito K; Kikuchi S; Yamada M; Torii S; Yoshida M Arerugi; 1992 Jul; 41(7):772-7. PubMed ID: 1444830 [TBL] [Abstract][Full Text] [Related]
28. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Lehofer B; Bloder F; Jain PP; Marsh LM; Leitinger G; Olschewski H; Leber R; Olschewski A; Prassl R Eur J Pharm Biopharm; 2014 Nov; 88(3):1076-85. PubMed ID: 25460154 [TBL] [Abstract][Full Text] [Related]
29. Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers. Sidler-Moix AL; Dolci U; Berger-Gryllaki M; Pannatier A; Cotting J; Di Paolo ER Pediatr Crit Care Med; 2013 Feb; 14(2):e98-102. PubMed ID: 23287904 [TBL] [Abstract][Full Text] [Related]
30. Prediction and experimental determination of solute output from a Collison nebulizer. Ip AY; Niven RW J Pharm Sci; 1994 Jul; 83(7):1047-51. PubMed ID: 7965663 [TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Desai TR; Tyrrell GJ; Ng T; Finlay WH Pharm Res; 2003 Mar; 20(3):442-7. PubMed ID: 12669966 [TBL] [Abstract][Full Text] [Related]
32. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Gessler T; Schmehl T; Hoeper MM; Rose F; Ghofrani HA; Olschewski H; Grimminger F; Seeger W Eur Respir J; 2001 Jan; 17(1):14-9. PubMed ID: 11307743 [TBL] [Abstract][Full Text] [Related]
33. Surface active drugs significantly alter the drug output rate from medical nebulizers. Arzhavitina A; Steckel H Int J Pharm; 2010 Jan; 384(1-2):128-36. PubMed ID: 19825407 [TBL] [Abstract][Full Text] [Related]
34. Characterization and in vitro evaluation of the formoterol/cyclodextrin complex for pulmonary administration by nebulization. Thi TH; Azaroual N; Flament MP Eur J Pharm Biopharm; 2009 May; 72(1):214-8. PubMed ID: 19010412 [TBL] [Abstract][Full Text] [Related]
35. The function profile of compressed-air and ultrasonic nebulizers. Wu HL; Lin YZ; Wu WF; Huang FY Acta Paediatr Taiwan; 2003; 44(5):264-8. PubMed ID: 14964980 [TBL] [Abstract][Full Text] [Related]
36. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Cleland JL; Jones AJ Pharm Res; 1996 Oct; 13(10):1464-75. PubMed ID: 8899836 [TBL] [Abstract][Full Text] [Related]
37. Physical properties of antibiotic aerosols produced by jet and ultrasonic nebulizers. Takanami C; Goto Y J Aerosol Med; 1990; 3(1):45-52. PubMed ID: 10147674 [TBL] [Abstract][Full Text] [Related]
39. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. Köhler E; Sollich V; Schuster-Wonka R; Hühnerbein J J Aerosol Med; 2003; 16(1):37-46. PubMed ID: 12737683 [TBL] [Abstract][Full Text] [Related]
40. Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW Int J Pharm; 1999 Nov; 189(2):215-25. PubMed ID: 10536250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]